Fulcrum Therapeutics, Inc.

Good morning and welcome to Fulcrum Therapeutics' fourth quarter year-end 2020 conference call. Currently, all participants are in listen-only mode. There will be a question and answer session at the end of this call. I would now like to turn it over to Christy Warrick, Director of Investor Relations and Corporate Communications at Fulcrum. Please proceed.

Thank you, Operator. Good morning and welcome to the Fulcrum Therapeutics conference call to discuss our fourth quarter and full year 2020 financial results and recent corporate highlights. Earlier today, we issued a press release. For those of you who don't have a copy, you can access it in the investor relations section of our website at fulcrumtx.com. Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, financial development timelines, and financial projections. While these forward-looking statements represent our views as of today, they should not be relied upon as representing our views in the future. We may update these statements in the future, but we're not taking on an obligation to do so. Please refer to our most recent filings for the Securities and Exchange Commission for discussion of certain risks and uncertainties associated with our business. With me on today's call are Robert Gould, President and CEO, Brian Stewart, incoming President and CEO, Chris Moxham, Chief Scientific Officer, and Peter Thompson, Vice President of Finance and Accounting. Let me quickly run through this morning's agenda. Robert will begin the call with a corporate overview. Brian will give an update on the low-speed trial with LosMapimod for COVID-19 and review our upcoming data from the Redux 4 trial with LosMapimod for FSHD. Chris will then provide a more detailed review of our program in sickle cell disease and our product engine, and Peter will cover our financials. With that, it's my pleasure to turn the call over to Robert. Robert,

Thank you, Christy. Good morning, everyone, and thank you for joining us today. 2021 is poised to be another important year for Fulcrum, as we expect to have meaningful updates from multiple key initiatives. The full LUSMAPIMON data from Redux 4, late in the second quarter of this year, will provide new insights that will inform the clinical path forward in FSHD. Following data availability, we'll meet with the FDA to discuss the path to registration. With FTX6058, we'll have data from the phase one trial in healthy adult volunteers midyear, and we anticipate initiating a trial in people with sickle cell disease by the end of the year. We're also continuing our efforts to advance additional treatments for genetically defined rare diseases with FulcrumSeq, both internally and through our partnerships with the goal of bringing forward two INDs over the next 24 months. This morning, we also announced my retirement and that Brian Stewart, who has been our chief operating officer since 2018, will be promoted to president and CEO at the end of this month. I look forward to staying engaged with Fulcrum as I continue on the board. Brian will join Fulcrum's board, and Mark Levin, our board chair, will assume the role of executive chair upon my retirement. As many of you know, Brian has been a key contributor to Fulcrum. His leadership within the organization and breadth of experience will be a key driver of our success going forward. In addition to his many accomplishments over the past two years, Brian has significant experience within the rare disease space, where he has played a critical role in helping to advance multiple successful programs through the clinic to commercialization. Brian's leadership will be invaluable as we advance our current clinical programs and continue to advance our pipeline with our product engine. To everyone at Fulcrum, I'm proud of the strong foundation we've built together, and I'm privileged to have worked alongside you. I look forward to serving as an advisor and working with Brian and the other board members as we drive continued success. With that, I'll turn it over to Brian. Brian? Thank you, Robert.